

Collaborative Working Project Executive Summary

| | |
|-------------------------------|---|
| Project title | A Collaborative Working Agreement between Sanofi and the Multiple Sclerosis Service within Barts Health NHS Trust to review and improve the patient journey and experience for patients with multiple sclerosis. |
| Partner organisation/s | <p>Barts Health NHS Trust, The Royal London Hospital, 80 Newark Street, London, E1 2ES</p> <p>Sanofi, 410 Thames Valley Drive, Reading, Berkshire, RG6 1PT</p> |
| Project rationale | <p>Barts Health NHS Trust operates from four major hospital sites (The Royal London, St Bartholomew's, Whipps Cross and Newham). The Neurology Department at Royal London Hospital provides a full range of District General Hospital (DGH) services and some regional specialties for a catchment area of around 2.5 million people living in the London Boroughs of Tower Hamlets, Waltham Forest and Newham.</p> <p>Approximately 150,000 patients live with Multiple Sclerosis (MS) in the UK and around 7,000 people are newly diagnosed each year. Bart's neurology waiting list consists of around 2,500 new patients waiting as of February 2025. The department is performing poorly on the Referral to Treatment Waiting Times with only 45.2% seen within 18 weeks of referral compared to NHS Operational Standard of 92%. The wait to be seen for treatment is up to one year which is therefore significantly impacting on new patients starting treatment.</p> <p>Despite current MS management for acute inflammation and relapses, patients continue to experience disease progression resulting in disability accumulation. DMTs (disease modifying treatments) are available for the treatment of MS and they are managed in secondary care in the North East London area. DMTs involve the regular utilisation of specialist hospital services. The financial burden is a particular concern with District General Hospitals who feel that they are losing out on income due a lack service level agreement between the Trusts and the ICB's. One of the key objectives of this project is to gather evidence of the financial implications that are attached to the outpatient visits, blood monitoring and unplanned admissions for patients with MS.</p> <p>Barts Health NHS Trust wants to conduct a review of the MS service as they recognise the need to understand where efficiencies in the process can help them free clinical capacity which in turn, will support them to reduce the waiting lists, improve efficiencies for patients & staff and build resilience in the service to allow them to grow. This collaborative working project is aimed at reviewing the current pathway and service, the outcome being to provide a list of options for service improvement. In addition, there are potential service changes that could be explored which would enable some of the MS services, currently delivered in hospital, to be delivered closer to patients' homes and potentially within patients' homes.</p> |

| | |
|---------------------------|--|
| Project period | 2025 Quarter 2 to 2025 Quarter 4 |
| Project objectives | <p>The collaborative working project will aim to deliver the following benefits for Patients, the NHS and Sanofi:</p> <p>Patients:</p> <ul style="list-style-type: none"> • The feasibility of improved, timely access to MS services in the patient's preferred location. • The possibility of improved specialist service access for treatment options requiring hospital delivery. <p>NHS:</p> <ul style="list-style-type: none"> • Achieve an improved understanding of current service delivery for MS patients. • Develop insight of where the service could potentially be provided to benefit patients and improve service delivery. • The possibility of improved specialist service capacity for treatment options requiring hospital outpatient delivery. <p>Sanofi:</p> <ul style="list-style-type: none"> • Improved understanding of the pressure points and priorities associated with treatment delivery for MS patients. • Improved corporate reputation within Barts. • As Sanofi produce medicines within this disease area if overall patient care is optimised there may be an increase in the usage of these products in line with national and local guidelines. Sanofi has a product in MS that is under regulatory and reimbursement review in 2025. <p>As a result of the project, there could also be an increase in the usage of other medications made by other pharmaceutical companies in line with national and local guidelines.</p> <p>This project will be supported by pooling of resources approximately £10,137 (Sanofi 51%, NHS 49%)</p> |
| Contact details | <p><u>Barts Health NHS Trust</u></p> <p>Dr S Gnanapavan Lead Consultant Neurologist Barts Health NHS Foundation Trust The Royal London Hospital, 80 Newark Street, London, E1 2ES</p> |

| | |
|--|--|
| | <p><u>Sanofi</u></p> <p>Paul Naish Head of Market Access UK&IE Sanofi 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT. GB-patientaccess@sanofi.com</p> |
|--|--|